The presentations will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

SOURCE Dendreon Corporation

http://www.dendreon.com

If approved by the FDA, PROVENGE would represent the first product in a new therapeutic class known as active cellular immunotherapies.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including the FDA's actions with respect to the BLA and whether the FDA determines to convene an advisory committee to review the BLA; progress on the commercialization efforts for PROVENGE, including the expansion of Dendreon's manufacturing capacity and other necessary infrastructure; success in the hiring of additional personnel to support business growth and expansion; the outcome of pre-approval inspection of Dendreon's expanded manufacturing facility; and requisite receipt of FDA licensure for marketing of PROVENGE and the risk that additional capital could be needed in the future for the potential commercialization of PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

SOURCE Dendreon Corporation

http://www.dendreon.com

In a press release out on November 20, Dendreon Receives FDA Acknowledgement of Complete Response

---- PDUFA Date Assigned as May 1, 2010 --

SEATTLE, Nov 20, 2009 -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE(R) (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visitwww.dendreon.com.

POZEN Inc. (NASDAQ: POZN) trading at $6.76 per share on trading volume of 74,500 shares.

In a press release out on November 20, POZEN Announces Start of Enrollment For PA32540 Phase 3 Program

CHAPEL HILL, N.C., Nov 20, 2009 -- POZEN Inc. (NASDAQ: POZN) announced today the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.

About POZEN

POZEN Inc., headquartered in Chapel Hill, NC, is a pharmaceutical company committed to transforming medicine that transforms lives. Since its founding in 1996, POZEN has successfully created novel pharmacologic agents primarily for pain and pain-related conditions by combining existing drug therapies that result in superior patient outcomes. Moving forward, POZEN is poised to become a model 21st Century pharmaceutical company dedicated to ensuring that they produce cost-effective, evidence-based medicines; take a fresh approach to sales, marketing and medical education; and deliver high-quality, affordable pharmaceuticals to our customers. The company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For more detailed company information, including copies of this and other press releases, please visit: www.POZEN.com.

ValueClick, Inc. (Nasdaq:VCLK) trading at $10.07 on a volume of 305,870 shares

In a press release out on November 20, ValueClick to Present at Upcoming Investor Conferences

WESTLAKE VILLAGE, Calif., Nov 20, 2009 -- ValueClick, Inc. (Nasdaq:VCLK) today announced that senior management will present at the following investor conferences:

-- Friday, November 20 at 9:10 a.m. ET at the Citi Investment Research Small and Mid Cap Conference in New York; and

-- Tuesday, December 8 at 9:30 a.m. ET at the UBS 37th Annual Global Media and Telecommunications Conference in New York.

Presentation materials and webcast links to the presentations will be available on the Investor Relations section of www.valueclick.com.

About ValueClick, Inc.

ValueClick, Inc. (Nasdaq:VCLK) is one of the world's largest online marketing services companies, offering comprehensive and scalable solutions to deliver cost-effective customer acquisition for advertisers and robust revenue streams for publishers. ValueClick's performance-based solutions allow customers to reach their potential through multiple online marketing channels, including affiliate and search marketing, display advertising, lead generation, ad serving and email technology, and comparison shopping. ValueClick brands include Commission Junction, ValueClick Media, Mediaplex, Smarter.com, CouponMountain.com, and PriceRunner. For more information, please visit www.valueclick.com.

Nuance Communications (NASDAQ: NUAN) trading at $13.64 on a volume of 336,816 shares

In a press release out on November 20, Nuance Vocalizer for Automotive Now Shipping in More Mio Devices Worldwide

Mio Technology to Further Integrate Nuance's Innovative Text-to-Speech as Part of its Global Personal Navigation Device Portfolio

BURLINGTON, Mass. & AACHEN, Germany, Nov 20, 2009 -- Nuance Communications (NASDAQ: NUAN) today announced that it has extended its relationship with Mio Technology, which develops and markets products including personal navigation devices, to meet the latest developments in mobile services with Nuance Vocalizer for Automotive text-to-speech. As part of the relationship, Mio will bring Nuance's text-to-speech to a broader range of its personal navigation devices. Nuance Vocalizer for Automotive is optimized for personal navigation devices and will enable Mio's customers to enjoy the ease and convenience of a speech-enabled mobile experience from behind the wheel.

About Nuance Mobile

Nuance Mobile builds innovative, intelligent and intuitive touch and speech interfaces to simplify and enhance the way people interact with mobile devices, applications, and services. Nuance Mobile solutions make mobile devices and in-car systems easier to use, automate customer self-service, and optimize the access and discovery of even the most advanced mobile applications and content -- regardless of technical know-how, location, environment, or physical and literacy capabilities.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com e-mail: Info@xtremepicks.com WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Expected next investor conference call information:
Conference Call Date: 11/11/2009
Conference Call Time (ET): 4:30 PM
Conference Call URL: http://investor.dendreon.com/eventdetail.cfm?EventID=74221